Monthly Archives: November 2014

Biothera Names Dr. Jeremy Graff SVP of Pharmaceutical Research

Biothera Names Dr. Jeremy Graff SVP of Pharmaceutical Research

EAGAN, MN — November 19, 2014 — Biothera announced today the appointment of Jeremy R. Graff, Ph.D., as Senior Vice President, Research, for its Pharmaceutical Group. Most recently, Dr. Graff served as a Research Fellow and Group Leader, Oncology Patient Tailoring at Eli Lilly and Company. Dr. Graff has extensive experience across the spectrum of drug discovery and development, having led numerous programs from target...

Read More


Biothera Names Carey Anderson VP of Regulatory Affairs

Biothera Names Carey Anderson VP of Regulatory Affairs

EAGAN, MN — November 13, 2014 — Carey Anderson has joined Biothera as Vice President of Regulatory Affairs for its Pharmaceutical business. Ms. Anderson has more than 18 years of global regulatory experience. Her previous positions include Director and Global Regulatory Lead at Amgen, Senior Director of Global Regulatory Affairs at Baxter Healthcare, and Director of Regulatory and Quality Assurance at Acceleron Pharma and Merrimack...

Read More


Biothera’s Imprime PGG Named to Top 10 List of Most Interesting Oncology Projects to Watch

EAGAN, MN — November 12, 2014 — Biothera has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its cancer immunotherapy candidate Imprime PGG®. Products selected as one of the Most Interesting Oncology Projects to Watch have met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and...

Read More


Biothera’s Imprime PGG Inhibits Cancer Defense Mechanism

Biothera’s Imprime PGG Inhibits Cancer Defense Mechanism

New Data Shows Immunotherapy Drug Candidate Prevented M2 Polarization of Macrophages EAGAN, MN — November 6, 2014 — New data demonstrates that Biothera’s immunotherapy drug candidate inhibits a cancer defense mechanism that recruits and polarizes certain immune cells for its own protection and growth. The in vitro research will be presented tomorrow at the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD. Numerous...

Read More